Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?-Reference-Cited by-同舟云学术

Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?

Published:2019-03-28 Issue:6 Volume:8 Page:e1581528
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Davola Maria Eugenia¹,Mossman Karen Louise¹^ORCID

Affiliation:

1. Department of Pathology and Molecular Medicine, McMaster Immunology Research Centre, Michael DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://tandfonline.com/doi/pdf/10.1080/2162402X.2019.1596006

Reference80 articles.

1. 1,496 clinical trials on ClinicalTrials.gov with “cancer AND immunotherapy” as search terms. ClinicalTrials.gov: US National Library of Medicine; 2019 [accessed 2019 Jan 23].

2. Talimogene Laherparepvec for the Treatment of Advanced Melanoma

3. Trial Watch—Oncolytic viruses and cancer therapy

4. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

5. Oncolytic viruses as engineering platforms for combination immunotherapy

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer;Pharmaceutics;2024-09-07

3. Breaking Barriers: Animal Viruses as Oncolytic and Immunotherapeutic Agents for Human Cancers;Virology;2024-09

4. A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-07

5. Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures;eBioMedicine;2024-07